National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301/496–7736 ext. 244; fax: 301/402–0220; e-mail: sanhaiw@od.nih.gov. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

A Mouse Model of von-Hippel Lindau Disease

Laura S. Schmidt et al. (NCI) DHHS Reference No. E-264-01/0

The current invention embodies a mouse model which has been rendered a conditional homozygous knockout at the murine chromosome 6 VHL locus, homologous to the human VHL locus at chromosome 3p25. Mutations in VHL, a tumor suppressor gene, lead to the clinical manifestations of von Hippel-Lindau disease, a rare autosomal dominant syndrome characterized by tumor formation in multiple organs, including the brain and kidneys. Using Cre/lox site-specific recombination, this invention allows for homozygous deletion of wild-type VHL only in specified tissues, thereby circumventing the embryonic lethality seen in the VHL knockout mouse. The model embodied in this invention therefore appears to represent a valuable research tool for understanding how inactivation of both copies of the VHL gene lead to tumor formation, and ultimately should aid in the testing of possible therapeutic approaches to von Hippel-Lindau disease.

A Mouse Model of Multiple Endocrine Neoplasia, Type I

Judy S. Crabtree, Francis S. Collins (NHGRI)

DHHS Reference No. E-243-01/0

The current invention embodies a mouse model which is heterozygous for a null allele at the Men1 locus of murine chromosome 19. Men1 has similar exonintron organization and amino acid identity compared with its human analog MEN1, which has been implicated in the pathogenesis of multiple endocrine neoplasia, type I (MENI). This mouse model has been shown to develop features remarkably similar to those of MEN1, which include tumors of the endocrine pancreas, pituitary, and parathyroids. The model embodied in this invention appears to represent a valuable research tool for use in elucidating the role of the wildtype Men1 allele in tumor formation, and ultimately should aid in the testing of possible therapeutic approaches to human MEN1.

Dated: August 8, 2001.

Jack Spiegel,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 01–20424 Filed 8–13–01; 8:45 am] BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Center for Research Resources; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Center for Research Resources Special Emphasis Panel, Comparative Medicine

Date: October 4, 2001.

Time: 7:30 p.m. to Adjournment.

Agenda: To review and evaluate grant applications and/or proposals.

Place: The Madison Concourse Hotel, One West Dayton Street, Madison, WI 53703.

Contact Person: Camille M. King, PhD, Scientific Review Administrator, Office of Review, National Center for Research Resources, National Institutes of Health, One Rockledge Centre, MSC 7965, 6705 Rockledge Drive, Suite 6018, Bethesda, MD 20892–7965, (301) 435–0815, kingc@ncrr.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine, 93.306; 93.333, Clinical Research, 93.333; 93.371, Biomedical Technology; 93.389, Research Infrastructure, National Institutes of Health, HHS)

Dated: August 8, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 01–20421 Filed 8–13–01; 8:45 am]
BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Center for Research Resources; Notice of Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings.

The meetings will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Scientific and Technical Review Board on Biomedical and Behavioral Research Facilities.

Date: September 24-25, 2001.

Open: September 24, 2001, 8 a.m. to 9 a.m. Agenda: To discuss program planning and other issues.

Place: DoubleTree Hotel, 1750 Rockville Pike, Rockville, MD 20852.

Closed: September 24, 2001, 9 a.m. to Adjournment.

Agenda: To review and evaluate grant applications.

Place: DoubleTree Hotel, 1750 Rockville Pike, Rockville, MD 20852.

Contact Person: D.G. Patel, PhD, Scientific Review Administrator, Office of Review, National Center for Research Resources, National Institutes of Health, 6705 Rockledge Drive, Room 6018, Bethesda, MD 20892— 7965, (301) 435–0824, dgpatel@ncrr.nih.gov.

Name of Committee: National Center for Research Resources Initial Review Group, General Clinical Research Centers Review Committee.

Date: October 10-11, 2001.

Open: October 10, 2001 8 a.m. to 9:30 a.m. Agenda: To discuss program planning and other issues.

Place: Holiday Inn-Chevy Chase, 5520 Wisconsin Avenue, Chevy Chase, MD 20815. Closed: October 10, 2001, 9:30 a.m. to Adjournment.

Agenda: To review and evaluate grant applications.

Place: Holiday Inn-Chevy Chase, 5520 Wisconsin Avenue, Chevy Chase, MD 20815.